Linvatec Corp, a wholly-owned subsidiary of Bristol-Myers Squibb, hasbeen acquired by the CONMED Corp. Terms of the acquisition of Linvatec, a surgical device company, include a cash purchase price of $370 million, subject to certain adjustments. In addition, B-MS has received a 10-year warrant to purchase one million shares of CONMED stock at a price equal to $34.23 per share. Linvatec had revenues of approximately $215 million in 1996 and employs 850 people.
- Meantime, B-MS has acquired Redmond Products, a privately-owned US hair care company which has sales of some $130 million per year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze